rss
Br J Ophthalmol 2004;88:1228 doi:10.1136/bjo.2004.042838
  • Mailbox

Macular infarction after intravitreal amikacin: authors’ reply

  1. G D Galloway,
  2. A Ramsay,
  3. K Jordan,
  4. A Vivian
  1. Addenbrooke’s Hospital, Cambridge, UK
  1. Correspondence to: G D Galloway Addenbrooke’s Hospital, Cambridge, UK; gavgaldoctors.net.uk
  • Accepted 22 January 2004

We thank Doft et al for their useful and expert opinion.1 The choice of which agent to use to empirically treat Gram negative organisms implicated in endophthalmitis remains controversial. As amikacin has been proved to cause macular infarction, we think one should look at viable alternatives. Ceftazidime is already in widespread use in the United Kingdom and appears not …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.